Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.
Facebook
Twitterhttps://meyka.com/licensehttps://meyka.com/license
AI-powered price forecasts for ZIOP stock across different timeframes including weekly, monthly, yearly, and multi-year predictions.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported 16.04M in Outstanding Shares in April of 2024.Data for Alaunos Therapeutics | ZIOP - Outstanding Shares including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $45.2M in Market Capitalization this March of 2026, considering the latest stock price and the number of outstanding shares.Data for Alaunos Therapeutics | ZIOP - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $843K in Trade Creditors for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $10.99M in Debt for its fiscal quarter ending in March of 2023.Data for Alaunos Therapeutics | ZIOP - Debt including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $3.72M in Assets for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Assets including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $1.19M in Operating Expenses for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-21.02M in EBITDA for its fiscal quarter ending in March of 2021.Data for Alaunos Therapeutics | ZIOP - Ebitda including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $2K in Sales Revenues for its fiscal quarter ending in March of 2025.Data for Alaunos Therapeutics | ZIOP - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-1.16M in Net Income for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Net Income including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $2.8M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Equity Capital And Reserves including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $4.47M in Loan Capital for its fiscal quarter ending in June of 2022.Data for Alaunos Therapeutics | ZIOP - Loan Capital including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $2K in Trade Debtors for its fiscal quarter ending in June of 2025.Data for Alaunos Therapeutics | ZIOP - Trade Debtors including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $0 in Cost of Sales for its fiscal quarter ending in September of 2024.Data for Alaunos Therapeutics | ZIOP - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $585K in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Selling And Administration Expenses including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $921K in Current Liabilities for its fiscal quarter ending in September of 2025.Data for Alaunos Therapeutics | ZIOP - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-1.13M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.Data for Alaunos Therapeutics | ZIOP - Gross Profit On Sales including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported $-7.84M in Pre-Tax Profit for its fiscal quarter ending in December of 2023.Data for Alaunos Therapeutics | ZIOP - Pre Tax Profit including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics reported 1 in Employees for its fiscal year ending in December of 2023.Data for Alaunos Therapeutics | ZIOP - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last March in 2026.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Alaunos Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.